Alpha CrossLaps® (CTX-I) EIA
Product Description
For the determination of non-isomerised fragments of C-terminal telopeptides of Type-I collagen (α CTX-I) in human urine. Results may be used as an aid in the identification of skeletal metastases in patients with breast and prostate cancer. Measurements of α CTX-I may be considered as an aid in the diagnosis of Paget’s disease and monitoring of anti-resorptive therapy in patients with Paget’s disease.
- Supports clinical assessment in cases of pathological high bone turnover
- Part of a complete assay panel supporting bone disease management
-
1. Alexandersen et al. Non-Isomerized C-Telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget ́s disease of bone.
2. Cloos et al. Investigation of bone diseases using isomerised and racemised fragments of type I collagen. Calcif Tissue Int (2003);72:8-17.
3. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB: The relative use of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 15: 32-8, 2006.
4. Cloos et al. Breast cancer patients with bone metastases are characterised by increasing levels of non-isomerised type I collagen fragments. Breast Cancer Res (2003);5:R103-9.
5. Cloos et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Cli. Lab. (2004); 50:279-289.
6. Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tanko LB, Byrjalsen I: Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomarkers Prev 15: 1392-5, 2006
- Product Code: AC-04F1
- Number of Tests: 96 wells
- Sample Type: Urine
- Sample Volume: 25 μL
- Assay Range: up to 5.5 ng/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| Serum Crosslaps® (CTX-I) ELISA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| N-MID® Osteocalcin | CE Marked | i10iSYS | Bone Turnover | Endocrinology | IVD |
| Ostase® BAP | CE MarkedFDA Cleared | i10iSYS | Bone TurnoverCKD-MBD | Endocrinology | IVD |
| Urine CrossLaps® (CTX-I) EIA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| Urine BETA CrossLaps® (CTX-I) ELISA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| BoneTRAP® (TRAcP 5b) ELISA | CE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD |